Recently, the serrated pathway to colorectal cancer, in which serrated polyps develop into cancers, has received much attention as an alternative pathway in colorectal carcinogenesis. Serrated polyps are categorised into three main subtypes: hyperplastic polyps, sessile serrated adenoma-polyps (SSA/P), and traditional serrated adenoma, according to the latest World Health Organization (WHO) classification ([@bib38]). Of these, SSA/P is reported to develop predominantly in the proximal colon and caecum (right-side colon), and also to harbour frequent *B-RAF* mutations ([@bib22]; [@bib15]; [@bib40]). Moreover, it has been reported that *MINT* or *p16* genes, markers of a CpG island methylator phenotype (CIMP), are methylated in SSA/P ([@bib33]; [@bib24]). As right-side colon cancers frequently show a microsatellite instability (MSI) phenotype owing to methylation of the *MLH1* gene, SSA/P is a putative precursor lesion for MSI cancer ([@bib8]; [@bib18]; [@bib4]). However, only several genes, most of which are CIMP markers, have been investigated for methylation analysis in SSA/P tissues. Recently [@bib12] performed genome-wide methylation analysis of colorectal polyps including SSA/P specimens and cancers, but they did not show any specific methylated genes that might be involved in SSA/P development. Moreover, it remains unknown whether or not the epi-driver genes are silenced by aberrant methylation and thereby contribute to the development of SSA/P.

Aberrant crypt foci (ACF), methylene blue-stainable crypts in the colorectum, are the earliest precancerous lesion in rodent models of colorectal carcinogenesis ([@bib5]). We previously observed human ACF using magnifying endoscopy; a significant correlation between the number of adenomas and number/size of rectal ACF in adenoma patients was demonstrated, and the ACF were frequently positive for *K-RAS* mutation ([@bib41], [@bib43], [@bib44]). Moreover, we and other investigators have shown that the number of rectal ACF is significantly higher in patients with colorectal adenomas and cancers than in normal subjects, suggesting that ACF are a precursor lesion of adenomas and cancers ([@bib41]; [@bib19]; [@bib36]; [@bib23]), although some contradictory studies have also been reported ([@bib7]; [@bib31]). To date, there have been only a few studies on ACF in the right-side colon ([@bib39], [@bib10]). However, no studies have investigated ACF in the right-side colon in patients with serrated polyps including SSA/P, and the relationship between ACF and SSA/P is currently unknown.

In this study, therefore, we performed analyses of *B-RAF* and *K-RAS* mutations, MSI, and genome-wide DNA methylation array using ACF in the right-side colon, SSA/P, and cancer in SSA/P specimens to clarify the molecular mechanism of the assumed ACF-SSA/P-cancer sequence. We also investigated the prevalence and number of ACF in the right-side colon of SSA/P patients compared with normal subjects to show a close association between SSA/P and ACF in the right-side colon.

Materials and methods
=====================

Subjects and study design
-------------------------

This study was approved by the ethics committee of Tokushima University Hospital (Tokushima, Japan). We first enrolled 20 patients with SSA/P (without cancer) and 2 patients with cancers in SSA/P from January 2012 through March 2013. All the patients had been known or suspected to have SSA/P lesions in the colon and were referred to our hospital for endoscopic removal. We investigated the number of ACF in the ascending colon and caecum (defined as the right-side colon in this study) and biopsied them under magnifying endoscopy, after removal of the SSA/P lesions by endoscopic mucosal resection (EMR). The histological diagnosis of SSA/P was made independently by two pathologists (TF and KS) according to the criteria of WHO ([@bib38]). Only lesions diagnosed as SSA/P concordantly by the pathologists were used. We also investigated *B-RAF* and *K-RAS* mutations, and MSI in 15 ACF, 20 SSA/P, and 2 cancer in SSA/P specimens, and performed genome-wide DNA methylation array analysis of seven ACF, seven SSA/P, and two cancer in SSA/P specimens. An additional 16 patients with SSA/P and 20 normal subjects were enrolled from August 2013 through February 2014 for assessment of ACF. Normal subjects were defined as subjects who were referred to our hospital for colonoscopy because of symptoms such as abdominal discomfort, distention, or a feeling of tightness on defecation, but with no apparent lesions of the colon observable by colonoscopy. Witten informed consent was obtained from all patients who had been known or suspected to have SSA/P before colonoscopy. For normal subjects, consent was obtained before colonoscopy to undergo ACF observation if no apparent lesion was identified. The baseline characteristics of patients with SSA/P are shown in [Supplementary Table 1](#sup1){ref-type="supplementary-material"}. The mean age and sex ratio (male/female) among patients with SSA/P and normal subjects were 62.1±13.0 years and 21 out of 17 *vs* 62.5±10.4 years and 11 out of 9, respectively.

ACF observation by magnifying endoscopy
---------------------------------------

A magnifying endoscope (model EC-L590ZW, FUJIFILM Holdings Corp., Tokyo, Japan) that magnifies objects by a factor of 135, equipped with an autofocusing device, was used throughout the examination. All subjects underwent total colonoscopy. In patients with SSA/P, after the SSA/P lesion was removed, the right-side colon was examined for ACF as previously described ([@bib41], [@bib43]). It was washed thoroughly with water, sprayed with 0.25% methylene blue solution, washed again thoroughly with water, and ACF were carefully identified using magnifying endoscopy. In normal subjects, after total colonoscopy, the right-side colon was examined for ACF using the same procedure. Regarding the accuracy of our ACF counting method, we previously reported that the inter-rater agreement rates and Cronbach\'s alpha were sufficiently high ([@bib42]). All procedures were recorded on videotape and evaluated by two independent observers who were unaware of the subjects\' clinical histories. ACF were defined as minute lesions identifiable under magnifying chromoendoscopy in which crypts were more darkly stained with methylene blue than normal crypts ([@bib35]; [@bib41]).

Two-PCR and RFLP for detection of *B-RAF* codon 600 and *K-RAS* codon 12 and 13 mutations
-----------------------------------------------------------------------------------------

*B-RAF* codon 600 and *K-RAS* codon 12 and 13 mutations were detected using a 2-step PCRRFLP method, as previously described ([@bib30]; [@bib9]; [@bib32]). In brief, cellular DNA was extracted from EMR or biopsy specimens of SSA/P or ACF and used as a template for PCR. The PCR products were amplified using mismatched primers and analysed by RFLP to detect point mutations in *B-RAF* codon 600 and in *K-RAS* codons 12 and 13. The cancer portion of the cancer in SSA/P tissue was macrodissected and DNA was extracted for PCR--RFLP analysis.

MSI analysis
------------

Microsatellite instability analysis was performed using cellular DNA as a template for PCR. The pentaplex PCR system that includes primer pairs for five microsatellite targets (BAT-25, BAT-26, D2S123, D5S346, and D17S250) was used according to the method of [@bib45]) with minor modification. Tumours with instability at ⩾2 markers were classified as high-degree microsatellite instability (MSI-H), at 1 marker as low-degree microsatellite instability (MSI-L), and at 0 markers as microsatellite stable (MSS).

DNA methylation array analysis
------------------------------

A genome-wide DNA methylation array analysis was performed using the microarray-based integrated analysis of methylation by isochizomers (MIAMI) method, as previously described ([@bib14]; [@bib16]; [@bib25]). In brief, this method utilises two isochizomers, *Hpa* II and *Msp* I, which recognise the same DNA sequence (CCGG). Genomic DNA was first digested with *Hpa* II, a methylation-sensitive restriction enzyme that only cleaves unmethylated DNA, and then adaptor-ligated and amplified by PCR with the primers for adaptor sequences. They were then digested with *Msp* I, a methylation-insensitive enzyme that digests CCGG sites irrespective of their methylation status, followed by amplification with the same set of primers (*Hpa* II-*Msp* I treatment). The second digestion with *Msp* I only yielded products from unmethylated DNA fragments. Therefore, only *Hpa*II-cleavable unmethylated DNA fragments were amplified. The amplified products were labelled with Cy3 or Cy5 and co-hybridised to a microarray spotted with 38172 oligonucleotides covering the vicinity of the transcription start sites of 15883 genes (Agilent ChIP-on-Chip Custom Microarray, Agilent Technologies, Santa Clara, CA, USA). After hybridisation, the membranes were scanned, and the fluorescence intensities were quantified and normalised. The same samples were digested first with *Msp* I instead of *Hpa* II (*Msp* I---*Msp* I treatment) and analysed on a duplicate array to correct for false-positives.

Methylation-specific PCR
------------------------

The bisulphite-modified DNA samples were used as a template for methylation-specific PCR (MSP). The methylation status of the sites in the *PQLC1*, *HDHD3*, *RASL10B*, *FLI1, GJA3*, *and SLC26A2* genes identified by methylation array analysis was investigated by MSP, as previously described ([@bib6]). The primers used for MSP are described in [Supplementary Table 2](#sup1){ref-type="supplementary-material"}.

Immunohistochemistry
--------------------

Immunohistochemical staining was performed using the streptavidin-biotin-peroxidase method with labelled streptavidin-biotin (LSAB, Dako, Kyoto, Japan), according to the manufacturer\'s instructions. Briefly, paraffin-embedded sections were deparaffinised in xylene and hydrated in graded ethanol solutions and phosphate-buffered saline. Endogenous peroxidase was inactivated by incubation with 0.3% H~2~O~2~--MeOH. Subsequently, the slides were heated in 0.01 [M]{.smallcaps} citrate buffer in a water bath at 95 °C (pH=6.0) for 15 min. Rabbit anti-human FLI1 polyclonal antibody ([@bib26]) (diluted 1 : 150, Santa Cruz Biotechnology, Santa Cruz, CA, USA), rabbit anti-human GJA3 polyclonal antibody ([@bib3]) (diluted 1 : 100, Funakoshi Co., Ltd Tokyo, Japan), and goat anti-human SLA26A2 polyclonal antibody ([@bib13]) (diluted 1 : 250, Sigma-Aldrich), rabbit anti-human PQLC1 polyclonal antibody (HPA051666) (diluted 1 : 150, Sigma-Aldrich, St Louis, MO, USA), rabbit anti-human HDHD3 polyclonal antibody (HPA024158) (diluted 1 : 100, Sigma-Aldrich) and rabbit anti-human RASL10B polyclonal antibody (HPA046842) (diluted 1 : 100, Sigma-Aldrich) were used as primary antibodies. Detailed data for the HPA antibodies are listed at the website <http://www.proteinatlas.org/>. The sections were incubated with primary antibodies, washed with PBS, and incubated with secondary biotinylated antibody from an LSAB+ peroxidase kit (Dako). Subsequently, the sections were incubated with streptavidin-horseradish peroxidase (HRP) conjugate and visualised with DAB chromogen (3\', 3-diaminobenzidine, Dako). Finally, the sections were counterstained with Mayer\'s hematoxylin.

Statistics
----------

All data were analysed using STATA version 8 software (Stata Corp., College Station, TX, USA). ANOVA was used to assess differences in the number of methylated genes among ACF, SSA/P, and cancer in SSA/P specimens. Scheffe\'s test was used to compare the numbers of methylated genes between the groups. The correlation between the number of SSA/P and the number of ACF was evaluated by Spearman\'s test. A *P*-value \<0.05 was considered significant.

Results
=======

Endoscopic appearance of SSA/P and ACF
--------------------------------------

[Figure 1A](#fig1){ref-type="fig"} shows a representative endoscopic view of SSA/P with a sessile isochromatic appearance in the ascending colon. Histological examination of this lesion revealed distorted and dilated crypts near the base with serrated architecture and no cytological dysplasia, consistent with SSA/P ([Figure 1B](#fig1){ref-type="fig"}) ([@bib15]; [@bib38]). [Figure 1C](#fig1){ref-type="fig"} shows a representative endoscopic view of ACF in the right-side colon of the same case. ACF could be identified as a focus consisting of abnormal crypts darkly stained with methylene blue. Histological examination revealed a serrated structure and distortion in some of the crypts but no cytological dysplasia ([Figure 1D](#fig1){ref-type="fig"}).

*B-RAF* and *K-RAS* mutations in ACF, SSA/P, and cancer in SSA/P
----------------------------------------------------------------

As *B-RAF* mutations at codon 600 are frequently positive in SSA/P tissues ([@bib22]; [@bib40]), we first examined *B-RAF* mutations in 15 ACF, 20 SSA/P, and 2 cancer in SSA/P specimens. *B-RAF* codon 600 mutations were detected in 16 out of 20 (80%) SSA/P specimens, consistent with previous reports ([@bib22]; [@bib40]). They were also detected in 10 out of 15 (66.7%) ACF and 2 out of 2 (100%) cancer in SSA/P specimens ([Figure 2A](#fig2){ref-type="fig"}). Thus, *B-RAF* mutations were frequently present in ACF, SSA/P, and cancer in SSA/P specimens, raising the possibility that the ACF in patients with SSA/P are precursor lesions of the SSA/P-cancer sequence.

We next examined *K-RAS* mutations at codon 12 and 13 because these mutations are frequently seen in rectal ACF, adenoma, and cancer ([@bib41], [@bib43]). However, *K-RAS* mutations at codon 12 were only detected in 2 out of 15 (13.3%) ACF, 2 out of 20 (10.0%) SSA/P, and 0 out of 2 (0%) cancerous portions in SSA/P specimens ([Figure 2B](#fig2){ref-type="fig"}). No *K-RAS* mutations at codon 13 were detected in any of the ACF, SSA/P, or cancer in SSA/P specimens ([Supplementary Figure 1](#sup1){ref-type="supplementary-material"}).

MSI in ACF, SSA/P, and cancer in SSA/P
--------------------------------------

As colorectal cancers with MSI develop predominantly in the right-side colon, we next examined MSI status in 15 ACF, 20 SSA/P, and 2 cancer in SSA/P specimens. All 15 ACF specimens were MSS, and there were no MSI-L, or MSI-H phenotypes. Of the 20 SSA/P specimens, 17 were MSS and 3 were MSI-L; however, none were MSI-H. While one of the cancer in SSA/P specimens was MSI-H (case 36) and the other was MSS (case 18). The latter cancer was positive for *p53* mutation ([Supplementary Figure 2](#sup1){ref-type="supplementary-material"}). These results for the cancer in SSA/P specimens were consistent with previous reports ([@bib20]; [@bib11]; [@bib28]; [@bib1]). The representative results of MSI analysis in ACF, SSA/P, and cancer in SSA/P are shown in [Supplementary Figure 3](#sup1){ref-type="supplementary-material"}.

DNA methylation array analysis of ACF, SSA/P, and cancer in SSA/P
-----------------------------------------------------------------

Genome-wide DNA methylation analysis of 7 ACF, 7 SSA/P, and 2 cancer in SSA/P specimens was performed using the MIAMI method in comparison with the corresponding normal colonic epithelia. As a majority of these three lesions were positive for *B-RAF* mutations, in this particular methylation analysis, all lesions with *B-RAF* mutations were analysed except for one ACF sample. Representative scatter plots of the signals from each probe in ACF (case 5), SSA/P (case 3), and cancer in SSA/P specimens (case 18) are shown in [Figure 3](#fig3){ref-type="fig"}. The values for log ((*Hpa*II intensity) lesion/(*Hpa*II intensity) normal) are plotted on the *x*-axis, representing the relative methylation changes of each lesion. The values for the log ((*Msp* I intensity) lesion/(*Msp*l intensity) normal) are plotted on the *y*-axis, representing the control for the enzyme effects at sample digestion. The threshold values were determined according to the original MIAMI method described by Hatada *et al* ([@bib14]). Dots located within the upper and lower green lines (± log 2, respectively) and on the right side of the yellow line at log 5 of the horizontal distance from the regression line of the plots represent hypermethylated genes in each lesion compared with paired normal colorectal epithelium: 9 genes were determined to be methylated in the ACF specimen. Likewise, 32 genes and 165 genes were methylated in SSA/P and cancer in SSA/P specimens, respectively. The mean number of methylated genes in ACF, SSA/P, and cancer in SSA/P specimens were 11.3±7.7, 37.0±17.3, and 193±39, respectively, showing a significant stepwise increment from ACF to SSA/P and then to cancer in SSA/P ([Figure 4](#fig4){ref-type="fig"}, *P*\<0.05).

On the basis of the results of the methylation array analysis, we searched for common methylated genes among the seven SSA/P tissues and found that *PQLC1* and *HDHD3* genes were the most commonly methylated genes; they were methylated in six out of seven cases (86%) ([Figure 5](#fig5){ref-type="fig"}). In addition, *RASL10B* gene was methylated in five out of seven cases (71%) and *FLI1*, *GJA3*, and *SLC26A2* genes were methylated in four out of seven cases (57%) respectively. All six genes were commonly methylated in the two cancer in SSA/P cases. In ACF tissues, *PQLC1* was methylated in three out of seven cases (43%); *SLC26A2, RASL10B* and *FLI1* genes were methylated in two out of seven cases (29%); and *GJA3* was methylated in one out of seven cases (14%). The methylation status of these genes, and *B-RAF*, *K-RAS* mutations and MSI status in each lesion are summarised in [Figure 5](#fig5){ref-type="fig"}.

Validation of methylation array analysis by MSP
-----------------------------------------------

To validate the results of methylation array analysis, we assessed the methylation status of the six genes by MSP. Bands of 500 bp representing methylation of *PQLC1* gene were detected in SSA/P tissues from cases 1--4, 6, and 7; ACF tissue from cases 5--7; and cancer tissues from cases 1 and 2 ([Figure 6](#fig6){ref-type="fig"}). However, no methylation bands were detected in SSA/P specimens that did not exhibit methylation in the methylation array analysis (data not shown). Thus, the methylation of *PQLC1* gene was validated by MSP. Likewise, methylation bands of *HDHD3* gene (450 bp), *RASL10B* gene (600 bp), *FLI1* gene (550 bp), *GJA3* gene (360 bp), and *SLC26A2* gene (350 bp) were confirmed in the corresponding specimens that exhibited methylation in the methylation array analysis. These data indicate that the methylation of all six genes was validated by MSP.

Expression of six genes in SSA/P tissues
----------------------------------------

To determine whether the expression of the six genes was silenced by aberrant methylation, we performed immunohistochemical staining on SSA/P tissues that showed methylation of the six genes; three SSA/P tissues were stained for expression of each gene. Representative staining patterns are shown in [Figure 7](#fig7){ref-type="fig"}. PQLC1, an unknown protein, showed staining in the cytoplasm and nucleus of normal epithelial cells. However, its staining was clearly diminished in the SSA/P cells ([Figure 7A](#fig7){ref-type="fig"}). HDHD3, also an unknown protein, was appreciably stained in the cytoplasm of normal epithelial cells, but its staining was markedly reduced in the SSA/P cells ([Figure 7B](#fig7){ref-type="fig"}). RASL10B, a small GTPase protein, was intensely stained in the cytoplasm of normal epithelial cells, but no such staining was present in the SSA/P cells ([Figure 7C](#fig7){ref-type="fig"}). FLI1 stained mainly the membrane of normal epithelial cells, whereas it was not stained in the SSA/P cells ([Figure 7D](#fig7){ref-type="fig"}). GJA3, a membrane protein, was stained predominantly in the membrane of normal epithelial cells, but was almost negative in the SSA/P tissue ([Figure 7E](#fig7){ref-type="fig"}). SLC26A2, an anion transporter, was present in the luminal side of normal epithelial cells. However, its staining was essentially negative in the SSA/P cells ([Figure 7F](#fig7){ref-type="fig"}). Thus, protein expression of the six genes was markedly decreased or silenced in all SSA/P tissues examined. These results strongly suggest that aberrant methylation of these genes causes silencing or a decrease of protein expression by inhibition of transcription.

Prevalence and number of ACF in patients with SSA/P and normal subjects
-----------------------------------------------------------------------

We also investigated the prevalence and number of ACF in the right-side colon of 38 SSA/P patients compared with 20 normal subjects using magnifying endoscopy to strengthen the hypothesis that ACF are a precursor lesion of the SSA/P-cancer sequence. The prevalence of ACF in SSA/P patients was 37out of 38 (97.4%), which was significantly higher than that in normal subjects (2 out of 20, 10.0%). The mean number of ACF in SSA/P patients was 3.79±2.11, which was significantly higher than that in normal subjects (0.10±0.33) (*P*\<0.01). Moreover, there was a significant positive correlation between the number of ACF and the number of SSA/P (*P*\<0.05) ([Supplementary Figure 4](#sup1){ref-type="supplementary-material"}). These data, in combination with epigenetic and genetic findings of ACF, suggest that ACF in the right-side colon are precursor lesions of the SSA/P-cancer sequence.

Discussion
==========

In this study, we found frequent *B-RAF* mutations in ACF of the right-side colon, SSA/P, and cancer in SSA/P, and also a stepwise increment of methylated genes in this order. Moreover, the number of methylated genes in ACF of right-side colon was 11.3±7.7 (range, 4--28), whereas it was only 1.3±1.0 (range, 0--2) in rectal ACF ([Supplementary Table 3](#sup1){ref-type="supplementary-material"}). Previously, we and other investigators showed that rectal (and sigmoidal) ACF are frequently positive for *K-RAS* mutations but not *B-RAF* mutations. These results suggest that ACF in the right-side colon is genetically distinct from rectal ACF and is a putative precursor lesion of the SSA/P-cancer sequence. Our results also suggest that *B-RAF* mutation is an early event associated with DNA methylation in colon carcinogenesis via SSA/P.

One out of the two cancer (in SSA/P) tissues showed an MSI-H phenotype with *MLH1* methylation, whereas the other one showed an MSS phenotype with p53 mutation. Although the number of cancer in SSA/P tissues examined was small, these results were consistent with previous reports indicating that there are two mechanistic pathways involved in the SSA/P-(dysplasia-) cancer sequence; one through *MLH1* methylation and the other through p53 mutation ([@bib20]; [@bib11]; [@bib28]; [@bib1]).

Our methylation array analysis revealed that six novel genes (*PQLC1*, *HDHD3*, *RASL10B*, *FLI1*, *GJA3*, and *SLC26A2*) were most frequently methylated, and their protein expression was suppressed in SSA/P tissues. The statistical power calculation revealed significant positivity of methylation in *PQLC1* (*P*\<0.01), *HDHD3* (*P*\<0.01), and *RASL10B* (*P*\<0.05) by Fisher\'s exact test. Similarly, there was marginal positivity of methylation in *FLI1*, *GJA3*, and *SLC26A2* (*P*=0.069). Moreover, all six genes were methylated in cancers in SSA/P tissues (100%), whereas, only some of them were methylated in ACF tissues. These results suggest that epigenetic silencing of these six genes has an important role in the development of SSA/P. Thus, our findings suggest an ACF-SSA/P-cancer sequence where ACF arise by *B-RAF* mutation and methylation of some of the six identified genes, then develop into SSA/Ps through accumulated methylation of these genes, and probably progress to cancer by additional epigenetic or genetic alterations. Interestingly, the expressions of these six genes were frequently suppressed in the right-side colon cancers with no apparent SSA/P as well, whereas they were not suppressed in most of the left-side colon cancers and adenomas as revealed by immunohistochemistry ([Supplementary Figure 5](#sup1){ref-type="supplementary-material"}). These results raise the possibility that these six genes have an important role in the right-side colon carcinogenesis.

Our clinical study revealed numerous ACF in the right-side colon of SSA/P patients, whereas there were only few ACF in the right-side colon of normal subjects. There was also a significant correlation between the number of ACF and the number of SSA/P in SSA/P patients. These results support the hypothesis that ACF in the right-side colon are a precursor lesion of the SSA/P-cancer sequence. It has been hypothesised that SSA/Ps develop through hyperplastic polyps, particularly through microvesicular hyperplastic polyps (MVHPs). As histological examination of ACF in the right-side colon revealed microvesicles in the crypts ([Figure 1D](#fig1){ref-type="fig"}), which is one of the characteristics of MVHP, we may assume a pathway from ACF to MVHP and subsequently to SSA/P. In the present study, however, we did not investigate ACF in the right-side colon from patients with other types of polyps including adenomas and traditional serrated adenomas. Therefore, it is not yet clear whether ACF in the right-side colon are specific to SSA/P or not. It will be important in the future to investigate ACF in these patients in comparison with ACF in patients with SSA/P.

It has been reported that marker genes for a CIMP such as *MINT1*, *MINT3*, *FGFBP3*, or SLIT2 are methylated in SSA/P tissues ([@bib22]; [@bib33]; [@bib21]; [@bib2]). In our study, however, methylation of these genes was seen in only one to two of the two SSA/P specimens, suggesting that these genes do not have a pivotal role in the development of SSA/P. In addition, the methylation sites of two genes identified (*PQLC1* and *SLC26A2*) were inside the CpG islands (defined as CpG observed/expected\>60%); interestingly, however, those of the remaining four genes were outside the CpG islands ([Supplementary Figure 6](#sup1){ref-type="supplementary-material"}). It is plausible that gene methylation at sites other than CpG islands are also involved in gene silencing in SSA/P tissues.

Of the six genes identified, *PQLC1* and *HDHD3* are not yet well characterised; their tissue distribution and function are unknown. The significance of epigenetic silencing of these genes in SSA/P as well as in colon tumours should be elucidated in detail in the future. RASL10B protein is a small monomeric GTPase with tumour suppressor potential, and epigenetic silencing of RASL10B in human HCC and breast cancer has been reported ([@bib47]; [@bib27]). Although reduced expression of RASL10B in colonic tumours has not yet been reported, it is presumed to function in normal colon epithelial cells as an oncosuppressive factor, as in HCC and breast cancer. FLI1 is an ETS family member and EWS/FLI1 fusion gene (11;22 translocation) that is known to have oncogenic activity in Ewing\'s sarcoma ([@bib29]). However, recently FLI1 expression was reportedly reduced by aberrant methylation in its promoter region in colorectal adenoma and cancer ([@bib34]). Therefore, *FLI1* epigenetic silencing may provide an advantage for cell growth in SSA/P cells. GJA3, same as connexin 46, is a gap junction protein ([@bib17]). In general, expression of the connexin gene family is downregulated in cancer cells in association with the promotion of cell proliferation, or enhanced invasiveness. Although the expression of GJA3 in colorectal tumours has not yet been reported, silencing of *GJA3* may contribute to promotion of cell proliferation and gap junction impairment resulting in crypt serration in SSA/P. Alternatively, it may be associated with mucin production because some connexins (e.g. connexin 30) are reportedly closely associated with mucin expression ([@bib37]). SLC26A2, also called diastrophic dysplasia sulphate transporter (DTDST), is an anion transporter and its epigenetic silencing in colon cancer cell lines has been reported recently by Yusa *et al* ([@bib46]). They also showed that knockdown of *SLC26A2* in a colon cancer cell line increased proliferation. Therefore, silencing of *SLC26A2* presumably promotes cell proliferation in SSA/P cells. However, there have been no reports to date indicating that patients with homozygous *SLC26A2*-inactivating germline mutation (diastrophic dysplasia) are predisposed to cancer. It is plausible that a single gene alteration without *B-RAF* mutation may not be sufficient for the development of SSA/P and subsequent cancer, although the possibility still remains that *SLC26A2* silencing might be a simple consequence of the process of SSA/P formation. Thus, epigenetic silencing of these six genes may provide an advantage for cell growth, formation of serrated architecture, or mucin production, all of which are characteristic findings of SSA/P.

In this study, we employed the MIAMI method, which has lower resolution and sensitivity compared with the most recent comprehensive methods using next generation sequencing technology, and successfully identified several candidate genes. The use of such the newest technologies for genome-wide screening of methylated genes (sites) will be able to identify additional genes that are differentially methylated in SSA/P. Therefore, further experiments using these technologies will be needed to provide a more detailed analysis of the underlying mechanisms of carcinogenesis via SSA/P in the colon.

In conclusion, our results suggest that ACF are precursor lesions of the SSA/P-cancer sequence in patients with SSA/P. Our data also suggest that the *B-RAF* mutation and accumulated aberrant methylation of the six novel genes (*PQLC1*, *HDHD3*, *RASL10B*, *FLI1*, *GJA3*, or *SLC26A2*) are closely associated with development of SSA/P.

We are grateful to Drs Shunto J and Kataoka K for referring SSA/P patients to our hospital, and Kajimoto M and Nakanishi Y for their expert technical assistance.

[Supplementary Information](#sup1){ref-type="supplementary-material"} accompanies this paper on British Journal of Cancer website (http://www.nature.com/bjc)

This work is published under the standard license to publish agreement. After 12 months the work will become freely available and the license terms will switch to a Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License.

The authors declare no conflict of interest.

Supplementary Material {#sup1}
======================

###### 

Click here for additional data file.

###### 

Click here for additional data file.

###### 

Click here for additional data file.

###### 

Click here for additional data file.

###### 

Click here for additional data file.

###### 

Click here for additional data file.

###### 

Click here for additional data file.

###### 

Click here for additional data file.

###### 

Click here for additional data file.

![**Endoscopic and histologic features of SSA/P (**A** and **B**) and ACF (**C** and **D**) in the right-side colon.** (**A**) Representative endoscopic view of SSA/P with 10 mm diameter. The size was estimated using biopsy forceps. (**B**) Histological examination showed serration in the lower crypt, and distorted, dilated, or anchor-shaped crypts (H&E staining). (**C**) Representative endoscopic view of ACF in the right-side colon from the same patient (case 7). ACF were identified by methylene blue staining under magnifying endoscopy. ACF consisted of larger and more darkly stained crypts than normal crypts. (**D**) Histological examinations showed serration and distortion of the crypts (H&E staining).](bjc2014545f1){#fig1}

![**Analysis for *B-RAF* codon 600 and *K-RAS* codon 12 mutations in ACF, SSA/P, and cancer in SSA/P.** Point mutations of *B-RAF* codon 600 and *K-RAS* codon 12 were examined using the 2-step PCR--RFLP method. (**A**) *B-RAF* mutations in ACF, SSA/P, and cancer in SSA/P. The HT-29 colon cancer cell line, which is known to have a *B-RAF* mutation, was used as a positive control. Normal colonic mucosa was used as a negative control. (**B**) *K-RAS* mutations in ACF, SSA/P, and cancer in SSA/P. The LS174T colon cancer cell line, which is known to have a *K-RAS* mutation, was used as a positive control. A1 represents ACF from case 1. S1 and C18 represent SSA/P and cancer in SSA/P from case 1 and case 18, respectively.](bjc2014545f2){#fig2}

![**Scatter plots of signals for each probe based on the microarray-based integrated analysis of methylation by isochizomers (MIAMI) method in ACF (**A**), SSA/P (**B**), and cancer in SSA/P (**C**).** Green lines represent *y*=± log2, blue lines represent *x*=± log5, and yellow lines are located at±log5 horizontal distance from the regression line (red line) of the plots in accordance with the original MIAMI method of [@bib14]. Dots located within the two green lines and on the right side of the yellow line were determined to be hypermethylated.](bjc2014545f3){#fig3}

![**Number of methylated genes in ACF, SSA/P, and cancer in SSA/P tissues.** The number of methylated genes detected using the MIAMI method in seven ACF, seven SSA/P, and two cancer in SSA/P specimens were plotted.](bjc2014545f4){#fig4}

![**Commonly methylated genes in SSAP tissues.** The most commonly methylated genes in seven SSA/P tissues were *PQLC1*, *HDHD3*, *RASL10B*, *FLI1*, *GJA3*, and *SLC26A2*. The methylation status of these six genes, and *B-RAF*, *K-RAS* mutations and microsatellite instability (MSI) status in seven ACF, seven SSA/P, and two cancer in SSA/P specimens are summarised. MSS, microsatellite stable; MSI-H, MSI-high.](bjc2014545f5){#fig5}

![**Analysis for DNA methylation in *PQLC1*, *HDHD3*, *RASL10B*, *FLI1*, *GJA3*, and *SLC26A2* by methylation-specific PCR.** P, commercially obtained positive control of methylated DNA. N, commercially obtained negative control of methylated DNA. N.M., normal colonic mucosa. M, methylated, U, unmethylated.](bjc2014545f6){#fig6}

![**Immunohistochemical staining for *PQLC1*, *HDHD3*, *RASL10B*, *FLI1*, *GJA3*, *and SLC26A2* in SSA/P tissues.** Representative staining patterns of *PQLC1* (**A**) *HDHD3* (**B**) *RASL10B* (**C**) *FLI1* (**D**) *GJA3* (**E**) and *SLC26A2* (**F**) are shown. Original magnification; **×**100. High-magnification images of each boxed area are shown in the inset (**×** 400).](bjc2014545f7){#fig7}
